Clearside Biomedical, Inc.: comprehensive income or loss

What this measure means

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Exact concept: us-gaap:ComprehensiveIncomeNetOfTax. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2014-01-01 to 2019-12-31. The SEC response was captured on 2026-09-21.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Related financial histories

• Clearside Biomedical, Inc.: total assets
• Clearside Biomedical, Inc.: total liabilities
• Clearside Biomedical, Inc.: stockholders equity
• Clearside Biomedical, Inc.: cash and cash equivalents
• Clearside Biomedical, Inc.: net income or loss
• Clearside Biomedical, Inc.: operating cash flow
• Clearside Biomedical, Inc.: capital expenditure payments
• Clearside Biomedical, Inc.: contract revenue excluding tax
• Clearside Biomedical, Inc.: financing cash flow
• Clearside Biomedical, Inc.: investing cash flow
• Clearside Biomedical, Inc.: retained earnings or deficit
• Clearside Biomedical, Inc.: basic weighted-average shares
• Clearside Biomedical, Inc.: diluted weighted-average shares
• Clearside Biomedical, Inc.: basic earnings per share
• Clearside Biomedical, Inc.: diluted earnings per share
• Clearside Biomedical, Inc.: net property, plant and equipment
• Clearside Biomedical, Inc.: share-based compensation expense
• Clearside Biomedical, Inc.: operating income or loss
• Clearside Biomedical, Inc.: current assets
• Clearside Biomedical, Inc.: current liabilities
• Clearside Biomedical, Inc.: current accounts payable
• Clearside Biomedical, Inc.: net current accounts receivable
• Clearside Biomedical, Inc.: operating expenses
• Clearside Biomedical, Inc.: research and development expense
• Clearside Biomedical, Inc.: common shares outstanding
• Clearside Biomedical, Inc.: cash including restricted cash
• Clearside Biomedical, Inc.: additional paid-in capital
• Clearside Biomedical, Inc.: operating lease right-of-use asset
• Clearside Biomedical, Inc.: operating lease liability
• Clearside Biomedical, Inc.: long-term debt
• Clearside Biomedical, Inc.: gross property, plant and equipment
• Clearside Biomedical, Inc.: accumulated depreciation on property, plant and equipment
• Clearside Biomedical, Inc.: other noncurrent assets
• Clearside Biomedical, Inc.: other noncurrent liabilities
• Clearside Biomedical, Inc.: accrued current liabilities
• Clearside Biomedical, Inc.: profit or loss including noncontrolling interests
• Clearside Biomedical, Inc.: general and administrative expense
• Clearside Biomedical, Inc.: depreciation expense
• Clearside Biomedical, Inc.: nonoperating income or expense
• Clearside Biomedical, Inc.: interest paid, net
• Clearside Biomedical, Inc.: operating lease payments

Inspect the source

Entity

Clearside Biomedical, Inc. / CIK 0001539029

Captured

2026-09-21T17:20:49.988Z

SEC response SHA-256

a1437e2d374588cac8926bbfdba573de86fcfd157d10f28f6b263d180fc3d71b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001539029.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))